Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention

Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75–90% needed to achiev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Public health (London) 2021-12, Vol.201, p.98-107
Hauptverfasser: Knight, H., Jia, R., Ayling, K., Bradbury, K., Baker, K., Chalder, T., Morling, J.R., Durrant, L., Avery, T., Ball, J.K., Barker, C., Bennett, R., McKeever, T., Vedhara, K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107
container_issue
container_start_page 98
container_title Public health (London)
container_volume 201
creator Knight, H.
Jia, R.
Ayling, K.
Bradbury, K.
Baker, K.
Chalder, T.
Morling, J.R.
Durrant, L.
Avery, T.
Ball, J.K.
Barker, C.
Bennett, R.
McKeever, T.
Vedhara, K.
description Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75–90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. & Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.
doi_str_mv 10.1016/j.puhe.2021.10.006
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8520885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0033350621004121</els_id><sourcerecordid>2600821889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-4ac792ca6336f37e27ca70aa80e37916458ba0bb51e886eb32e289e6217c26033</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCH-CALHHhkmVsJ46DEBJaClSq1AvlajnO7K5XWTvYSUT_PQ5bKuDAyfLM9954_Ah5wWDNgMk3h_Uw7XHNgbNcWAPIR2TFyloWlWTyMVkBCFGICuQZOU_pAAC8FtVTciZKBUyVYkWGW99hTKPxnfM7mg9qui5iSst1NtY6j3SPyWXE3lHn6bhHaoMf8cdIw5Zubr5dfSxY85Z2OGMfhiP6Xw1DO7fLsj6LRoxzLrvgn5EnW9MnfH5_XpDbT5dfN1-K65vPV5sP14UtlRiL0ti64dZIIeRW1Mhra2owRgGKumGyrFRroG0rhkpJbAVHrhqUnNWWy7z3BXl_8h2m9oidzdOj6fUQ3dHEOx2M0393vNvrXZi1qjgoVWWD1_cGMXyfMI366JLFvjcew5R0ngKKM6WajL76Bz2EKfq8XqY4V6xisFD8RNkYUoq4fXgMA70Eqg96CVQvgS61HGgWvfxzjQfJ7wQz8O4EYP7M2WHUyTr0FjsX0Y66C-5__j8Bc_2yWg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622815109</pqid></control><display><type>article</type><title>Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Knight, H. ; Jia, R. ; Ayling, K. ; Bradbury, K. ; Baker, K. ; Chalder, T. ; Morling, J.R. ; Durrant, L. ; Avery, T. ; Ball, J.K. ; Barker, C. ; Bennett, R. ; McKeever, T. ; Vedhara, K.</creator><creatorcontrib>Knight, H. ; Jia, R. ; Ayling, K. ; Bradbury, K. ; Baker, K. ; Chalder, T. ; Morling, J.R. ; Durrant, L. ; Avery, T. ; Ball, J.K. ; Barker, C. ; Bennett, R. ; McKeever, T. ; Vedhara, K.</creatorcontrib><description>Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75–90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. &amp; Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.</description><identifier>ISSN: 0033-3506</identifier><identifier>EISSN: 1476-5616</identifier><identifier>DOI: 10.1016/j.puhe.2021.10.006</identifier><identifier>PMID: 34801843</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Behavior change ; Context ; Coronaviruses ; COVID-19 ; COVID-19 Vaccines ; Digitization ; Disease transmission ; Dissemination ; Experts ; Humans ; Immunization ; Immunology ; Intervention ; Interviews ; Literature reviews ; Motivational interviewing ; Original Research ; Pandemics ; Population studies ; Public health ; Public participation ; SARS-CoV-2 ; Self-efficacy ; Severe acute respiratory syndrome coronavirus 2 ; Uptake ; Vaccination ; Vaccination Hesitancy ; Vaccine hesitancy ; Vaccines ; Viral diseases ; Workshops</subject><ispartof>Public health (London), 2021-12, Vol.201, p.98-107</ispartof><rights>2021 The Royal Society for Public Health</rights><rights>Copyright © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Dec 2021</rights><rights>2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. 2021 The Royal Society for Public Health</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-4ac792ca6336f37e27ca70aa80e37916458ba0bb51e886eb32e289e6217c26033</citedby><cites>FETCH-LOGICAL-c483t-4ac792ca6336f37e27ca70aa80e37916458ba0bb51e886eb32e289e6217c26033</cites><orcidid>0000-0001-6843-8250 ; 0000-0002-4602-3238 ; 0000-0001-8263-4151 ; 0000-0003-0775-1045</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0033350621004121$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,30976,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34801843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knight, H.</creatorcontrib><creatorcontrib>Jia, R.</creatorcontrib><creatorcontrib>Ayling, K.</creatorcontrib><creatorcontrib>Bradbury, K.</creatorcontrib><creatorcontrib>Baker, K.</creatorcontrib><creatorcontrib>Chalder, T.</creatorcontrib><creatorcontrib>Morling, J.R.</creatorcontrib><creatorcontrib>Durrant, L.</creatorcontrib><creatorcontrib>Avery, T.</creatorcontrib><creatorcontrib>Ball, J.K.</creatorcontrib><creatorcontrib>Barker, C.</creatorcontrib><creatorcontrib>Bennett, R.</creatorcontrib><creatorcontrib>McKeever, T.</creatorcontrib><creatorcontrib>Vedhara, K.</creatorcontrib><title>Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention</title><title>Public health (London)</title><addtitle>Public Health</addtitle><description>Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75–90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. &amp; Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.</description><subject>Behavior change</subject><subject>Context</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Digitization</subject><subject>Disease transmission</subject><subject>Dissemination</subject><subject>Experts</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunology</subject><subject>Intervention</subject><subject>Interviews</subject><subject>Literature reviews</subject><subject>Motivational interviewing</subject><subject>Original Research</subject><subject>Pandemics</subject><subject>Population studies</subject><subject>Public health</subject><subject>Public participation</subject><subject>SARS-CoV-2</subject><subject>Self-efficacy</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Uptake</subject><subject>Vaccination</subject><subject>Vaccination Hesitancy</subject><subject>Vaccine hesitancy</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Workshops</subject><issn>0033-3506</issn><issn>1476-5616</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNp9kUFv1DAQhS0EotvCH-CALHHhkmVsJ46DEBJaClSq1AvlajnO7K5XWTvYSUT_PQ5bKuDAyfLM9954_Ah5wWDNgMk3h_Uw7XHNgbNcWAPIR2TFyloWlWTyMVkBCFGICuQZOU_pAAC8FtVTciZKBUyVYkWGW99hTKPxnfM7mg9qui5iSst1NtY6j3SPyWXE3lHn6bhHaoMf8cdIw5Zubr5dfSxY85Z2OGMfhiP6Xw1DO7fLsj6LRoxzLrvgn5EnW9MnfH5_XpDbT5dfN1-K65vPV5sP14UtlRiL0ti64dZIIeRW1Mhra2owRgGKumGyrFRroG0rhkpJbAVHrhqUnNWWy7z3BXl_8h2m9oidzdOj6fUQ3dHEOx2M0393vNvrXZi1qjgoVWWD1_cGMXyfMI366JLFvjcew5R0ngKKM6WajL76Bz2EKfq8XqY4V6xisFD8RNkYUoq4fXgMA70Eqg96CVQvgS61HGgWvfxzjQfJ7wQz8O4EYP7M2WHUyTr0FjsX0Y66C-5__j8Bc_2yWg</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Knight, H.</creator><creator>Jia, R.</creator><creator>Ayling, K.</creator><creator>Bradbury, K.</creator><creator>Baker, K.</creator><creator>Chalder, T.</creator><creator>Morling, J.R.</creator><creator>Durrant, L.</creator><creator>Avery, T.</creator><creator>Ball, J.K.</creator><creator>Barker, C.</creator><creator>Bennett, R.</creator><creator>McKeever, T.</creator><creator>Vedhara, K.</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><general>The Royal Society for Public Health. Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6843-8250</orcidid><orcidid>https://orcid.org/0000-0002-4602-3238</orcidid><orcidid>https://orcid.org/0000-0001-8263-4151</orcidid><orcidid>https://orcid.org/0000-0003-0775-1045</orcidid></search><sort><creationdate>20211201</creationdate><title>Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention</title><author>Knight, H. ; Jia, R. ; Ayling, K. ; Bradbury, K. ; Baker, K. ; Chalder, T. ; Morling, J.R. ; Durrant, L. ; Avery, T. ; Ball, J.K. ; Barker, C. ; Bennett, R. ; McKeever, T. ; Vedhara, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-4ac792ca6336f37e27ca70aa80e37916458ba0bb51e886eb32e289e6217c26033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Behavior change</topic><topic>Context</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Digitization</topic><topic>Disease transmission</topic><topic>Dissemination</topic><topic>Experts</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunology</topic><topic>Intervention</topic><topic>Interviews</topic><topic>Literature reviews</topic><topic>Motivational interviewing</topic><topic>Original Research</topic><topic>Pandemics</topic><topic>Population studies</topic><topic>Public health</topic><topic>Public participation</topic><topic>SARS-CoV-2</topic><topic>Self-efficacy</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Uptake</topic><topic>Vaccination</topic><topic>Vaccination Hesitancy</topic><topic>Vaccine hesitancy</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Workshops</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knight, H.</creatorcontrib><creatorcontrib>Jia, R.</creatorcontrib><creatorcontrib>Ayling, K.</creatorcontrib><creatorcontrib>Bradbury, K.</creatorcontrib><creatorcontrib>Baker, K.</creatorcontrib><creatorcontrib>Chalder, T.</creatorcontrib><creatorcontrib>Morling, J.R.</creatorcontrib><creatorcontrib>Durrant, L.</creatorcontrib><creatorcontrib>Avery, T.</creatorcontrib><creatorcontrib>Ball, J.K.</creatorcontrib><creatorcontrib>Barker, C.</creatorcontrib><creatorcontrib>Bennett, R.</creatorcontrib><creatorcontrib>McKeever, T.</creatorcontrib><creatorcontrib>Vedhara, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Public health (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knight, H.</au><au>Jia, R.</au><au>Ayling, K.</au><au>Bradbury, K.</au><au>Baker, K.</au><au>Chalder, T.</au><au>Morling, J.R.</au><au>Durrant, L.</au><au>Avery, T.</au><au>Ball, J.K.</au><au>Barker, C.</au><au>Bennett, R.</au><au>McKeever, T.</au><au>Vedhara, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention</atitle><jtitle>Public health (London)</jtitle><addtitle>Public Health</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>201</volume><spage>98</spage><epage>107</epage><pages>98-107</pages><issn>0033-3506</issn><eissn>1476-5616</eissn><abstract>Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75–90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. &amp; Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34801843</pmid><doi>10.1016/j.puhe.2021.10.006</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6843-8250</orcidid><orcidid>https://orcid.org/0000-0002-4602-3238</orcidid><orcidid>https://orcid.org/0000-0001-8263-4151</orcidid><orcidid>https://orcid.org/0000-0003-0775-1045</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0033-3506
ispartof Public health (London), 2021-12, Vol.201, p.98-107
issn 0033-3506
1476-5616
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8520885
source Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Behavior change
Context
Coronaviruses
COVID-19
COVID-19 Vaccines
Digitization
Disease transmission
Dissemination
Experts
Humans
Immunization
Immunology
Intervention
Interviews
Literature reviews
Motivational interviewing
Original Research
Pandemics
Population studies
Public health
Public participation
SARS-CoV-2
Self-efficacy
Severe acute respiratory syndrome coronavirus 2
Uptake
Vaccination
Vaccination Hesitancy
Vaccine hesitancy
Vaccines
Viral diseases
Workshops
title Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T14%3A42%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20and%20addressing%20vaccine%20hesitancy%20in%20the%20context%20of%20COVID-19:%20development%20of%20a%20digital%20intervention&rft.jtitle=Public%20health%20(London)&rft.au=Knight,%20H.&rft.date=2021-12-01&rft.volume=201&rft.spage=98&rft.epage=107&rft.pages=98-107&rft.issn=0033-3506&rft.eissn=1476-5616&rft_id=info:doi/10.1016/j.puhe.2021.10.006&rft_dat=%3Cproquest_pubme%3E2600821889%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622815109&rft_id=info:pmid/34801843&rft_els_id=S0033350621004121&rfr_iscdi=true